Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for DCOY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 8.289M
March 31, 2026 7.821M
December 31, 2025 10.71M
September 30, 2025 4.810M
June 30, 2025 0.7949M
March 31, 2025 1.798M
December 31, 2024 2.434M
September 30, 2024 3.284M
June 30, 2024 3.273M
March 31, 2024 4.373M
December 31, 2023 5.900M
September 30, 2023 7.581M
June 30, 2023 11.54M
March 31, 2023 9.274M
December 31, 2022 12.11M
September 30, 2022 16.82M
June 30, 2022 22.65M
March 31, 2022
December 31, 2021 29.21M
September 30, 2021 31.90M
June 30, 2021 33.08M
March 31, 2021 36.61M
December 31, 2020 11.12M
September 30, 2020 9.558M
Date Value
June 30, 2020 7.223M
March 31, 2020 9.647M
December 31, 2019 3.739M
September 30, 2019 4.000M
June 30, 2019 6.514M
March 31, 2019 7.298M
December 31, 2018 6.132M
September 30, 2018 12.96M
June 30, 2018 15.76M
March 31, 2018 23.95M
December 31, 2017 33.32M
September 30, 2017 38.93M
June 30, 2017 47.12M
March 31, 2017 52.81M
December 31, 2016 61.08M
September 30, 2016 67.33M
June 30, 2016 74.85M
March 31, 2016 84.38M
December 31, 2015 91.34M
September 30, 2015 99.16M
June 30, 2015 106.01M
March 31, 2015 110.52M
December 31, 2014 33.85M
September 30, 2014 36.29M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Palatin Technologies, Inc. 10.16M
Unicycive Therapeutics, Inc. 61.42M
Nuvectis Pharma, Inc. 22.16M
ACADIA Pharmaceuticals, Inc. 956.47M
Alnylam Pharmaceuticals, Inc. 3.308B